TGFB1 and hepatocellular carcinoma: To further corroborate the evidence of PRG4-drug synergistic interaction, we reproduced in vitro the biological process that resembles a more physiological situation, whereby TGFβ-stimulated CAFs secrete PRG4, that, in turn, improves the drug effectiveness of both sorafenib and regorafenib on HCC cells.